CDMO News
Lipella Re-Signs Manufacturing Agreement with Cook MyoSite for Clinical Pipeline Support
Clinical-stage biotechnology company Lipella Pharmaceuticals Inc. has announced the renewal of its manufacturing collaboration agreement with Cook MyoSite, Inc. The partnership will support the development of Chemistry, Manufacturing and Control (CMC) documentation for two of Lipella’s clinical-stage therapies, LP-10 and LP-310. The renewed agreement
5 June 2025
Stay ahead of trends and best practices
